Abstract
This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.
MeSH terms
-
BNT162 Vaccine
-
COVID-19*
-
Humans
-
Neoplasms* / drug therapy
-
SARS-CoV-2
-
Vaccines, Synthetic
-
mRNA Vaccines
Substances
-
Vaccines, Synthetic
-
mRNA Vaccines
-
BNT162 Vaccine